Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis
出版年份 2021 全文链接
标题
Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis
作者
关键词
-
出版物
LANCET ONCOLOGY
Volume 22, Issue 9, Pages 1265-1274
出版商
Elsevier BV
发表日期
2021-08-13
DOI
10.1016/s1470-2045(21)00333-8
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials
- (2020) Lijun Da et al. Frontiers in Pharmacology
- Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis
- (2020) Yi Yang et al. Frontiers in Pharmacology
- Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
- (2020) Abdulaali R. Almutairi et al. Frontiers in Oncology
- Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis
- (2020) Robin Park et al. Frontiers in Oncology
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
- (2019) Yucai Wang et al. JAMA Oncology
- The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
- (2019) Lihu Gu et al. BMC CANCER
- Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials?
- (2019) V Simmet et al. ANNALS OF ONCOLOGY
- Trends in clinical development for PD-1/PD-L1 inhibitors
- (2019) Jia Xin Yu et al. NATURE REVIEWS DRUG DISCOVERY
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Conducting Meta-Analyses inRwith themetaforPackage
- (2015) Wolfgang Viechtbauer Journal of Statistical Software
- In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias
- (2014) James P. Hunter et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents
- (2012) M. R. Shurin et al. CURRENT MEDICINAL CHEMISTRY
- Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis
- (2010) Mao Mao An et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Bevacizumab Increases Risk for Severe Proteinuria in Cancer Patients
- (2010) S. Wu et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now